JP7240512B2 - Pd-1阻害剤を投与することにより子宮頸がんを処置する方法 - Google Patents

Pd-1阻害剤を投与することにより子宮頸がんを処置する方法 Download PDF

Info

Publication number
JP7240512B2
JP7240512B2 JP2021545411A JP2021545411A JP7240512B2 JP 7240512 B2 JP7240512 B2 JP 7240512B2 JP 2021545411 A JP2021545411 A JP 2021545411A JP 2021545411 A JP2021545411 A JP 2021545411A JP 7240512 B2 JP7240512 B2 JP 7240512B2
Authority
JP
Japan
Prior art keywords
antibody
patients
cervical cancer
pharmaceutical composition
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021545411A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022530599A5 (cg-RX-API-DMAC7.html
JP2022530599A (ja
Inventor
マシュー・ジー・フュリー
イザレル・ロウィ
メリッサ・ディブヤ・マティアス
ナズミ・アリス・ヤマ-デン
ウェン・フュリー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Regeneron Pharmaceuticals Inc
Original Assignee
Regeneron Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of JP2022530599A publication Critical patent/JP2022530599A/ja
Priority to JP2022179201A priority Critical patent/JP2023011902A/ja
Publication of JP2022530599A5 publication Critical patent/JP2022530599A5/ja
Application granted granted Critical
Publication of JP7240512B2 publication Critical patent/JP7240512B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2021545411A 2020-05-26 2021-05-25 Pd-1阻害剤を投与することにより子宮頸がんを処置する方法 Active JP7240512B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022179201A JP2023011902A (ja) 2020-05-26 2022-11-09 Pd-1阻害剤を投与することにより子宮頸がんを処置する方法

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US202063029757P 2020-05-26 2020-05-26
US63/029,757 2020-05-26
US202063069942P 2020-08-25 2020-08-25
US63/069,942 2020-08-25
US202163160074P 2021-03-12 2021-03-12
US63/160,074 2021-03-12
US202163174474P 2021-04-13 2021-04-13
US63/174,474 2021-04-13
US202163181434P 2021-04-29 2021-04-29
US63/181,434 2021-04-29
US202163185881P 2021-05-07 2021-05-07
US63/185,881 2021-05-07
PCT/US2021/034000 WO2021242728A1 (en) 2020-05-26 2021-05-25 Methods of treating cervical cancer by administering the pd-1 inhibitor antibody cemiplimab

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022179201A Division JP2023011902A (ja) 2020-05-26 2022-11-09 Pd-1阻害剤を投与することにより子宮頸がんを処置する方法

Publications (3)

Publication Number Publication Date
JP2022530599A JP2022530599A (ja) 2022-06-30
JP2022530599A5 JP2022530599A5 (cg-RX-API-DMAC7.html) 2022-11-29
JP7240512B2 true JP7240512B2 (ja) 2023-03-15

Family

ID=76859703

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021545411A Active JP7240512B2 (ja) 2020-05-26 2021-05-25 Pd-1阻害剤を投与することにより子宮頸がんを処置する方法
JP2022179201A Pending JP2023011902A (ja) 2020-05-26 2022-11-09 Pd-1阻害剤を投与することにより子宮頸がんを処置する方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022179201A Pending JP2023011902A (ja) 2020-05-26 2022-11-09 Pd-1阻害剤を投与することにより子宮頸がんを処置する方法

Country Status (11)

Country Link
US (1) US20210403567A1 (cg-RX-API-DMAC7.html)
EP (1) EP4157464A1 (cg-RX-API-DMAC7.html)
JP (2) JP7240512B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230015954A (cg-RX-API-DMAC7.html)
CN (1) CN115666724A (cg-RX-API-DMAC7.html)
AU (1) AU2021280245A1 (cg-RX-API-DMAC7.html)
CA (1) CA3168738A1 (cg-RX-API-DMAC7.html)
IL (1) IL298273A (cg-RX-API-DMAC7.html)
MX (1) MX2022014734A (cg-RX-API-DMAC7.html)
TW (1) TWI899236B (cg-RX-API-DMAC7.html)
WO (1) WO2021242728A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20240043560A1 (en) * 2022-08-02 2024-02-08 Regeneron Pharmaceuticals, Inc. Methods of Treating Metastatic Castration-Resistant Prostate Cancer with Bispecific Anti-PSMA x Anti-CD28 Antibodies in Combination with Anti-PD-1 Antibodies
TWI887800B (zh) * 2022-10-12 2025-06-21 美商默沙東有限責任公司 經由皮下投予抗pd1抗體以治療癌症之組合物及方法
WO2026158432A1 (zh) * 2025-01-24 2026-07-30 江苏奥赛康生物医药有限公司 抗pd-1抗体-il-15前药的融合分子与化学治疗药物的组合及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2539411T3 (es) 1999-08-23 2015-06-30 Dana-Farber Cancer Institute, Inc. PD-1, receptor para la B7-4 y su utilización
DE60334303D1 (de) 2002-07-03 2010-11-04 Tasuku Honjo Immunpotenzierende zusammensetzungen
ES2367430T3 (es) 2002-12-23 2011-11-03 Wyeth Llc Anticuerpos contra pd-1 y sus usos.
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
GB0624500D0 (en) * 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
PT2170959E (pt) 2007-06-18 2014-01-07 Merck Sharp & Dohme Anticorpos para o receptor humano de morte programada pd-1
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EA201500417A1 (ru) 2008-08-25 2015-11-30 Эмплиммьюн, Инк. Композиции антагонистов pd-1 и способы применения
WO2010036959A2 (en) 2008-09-26 2010-04-01 Dana-Farber Cancer Institute Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
US8686119B2 (en) 2011-07-24 2014-04-01 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
ES2742379T3 (es) 2012-05-31 2020-02-14 Hoffmann La Roche Procedimientos de tratamiento del cáncer usando antagonistas de unión al eje de PD-1 y antagonistas de VEGF
US9175082B2 (en) 2012-05-31 2015-11-03 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
US10241115B2 (en) 2013-12-10 2019-03-26 Merck Sharp & Dohme Corp. Immunohistochemical proximity assay for PD-1 positive cells and PD-ligand positive cells in tumor tissue
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗pd-l1之人類抗體
TWI681969B (zh) * 2014-01-23 2020-01-11 美商再生元醫藥公司 針對pd-1的人類抗體
PT3134123T (pt) * 2014-02-21 2021-03-22 Nektar Therapeutics India Pvt Ltd Agonistas seletivos de il-2rbeta em combinação com um anticorpo anti-ctla-4 ou um anticorpo anti-pd-1
SG10201901057UA (en) 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
CA2874083C (en) * 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3254110B1 (en) 2015-02-03 2020-03-18 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
MA42971A (fr) 2015-03-13 2018-08-15 Cytomx Therapeutics Inc Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation
WO2016191751A1 (en) 2015-05-28 2016-12-01 Bristol-Myers Squibb Company Treatment of pd-l1 positive lung cancer using an anti-pd-1 antibody
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
IL261998B2 (en) 2016-04-07 2023-03-01 Chemocentryx Inc Reducing your burden by giving ccr1 antagonists in combination with pd-1 inhibitors or pd-l1 inhibitors
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
JP7348072B2 (ja) * 2017-06-01 2023-09-20 コンピュジェン リミテッド 三重併用抗体療法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
Annals of Oncology 29(suppl_10) (2018), X27-28
Clinical Cancer Research 26 (2020.03), 1025-1033
Expert Opin Drug Discov.,2018,Vol.13,No.5,p.445-457
frontiers in Pharmacology 10 (2019), Article 65
Gynecol.Oncol.,2020,Vol.159,No.2,p.322-328
Gynecologic Oncology 157 (2020.01), 161-166
Journal of Clinical Oncology 38(15_suppl)(2020.05.20), 10018

Also Published As

Publication number Publication date
US20210403567A1 (en) 2021-12-30
TW202210098A (zh) 2022-03-16
WO2021242728A1 (en) 2021-12-02
EP4157464A1 (en) 2023-04-05
CN115666724A (zh) 2023-01-31
TWI899236B (zh) 2025-10-01
JP2023011902A (ja) 2023-01-24
KR20230015954A (ko) 2023-01-31
CA3168738A1 (en) 2021-12-02
IL298273A (en) 2023-01-01
JP2022530599A (ja) 2022-06-30
AU2021280245A1 (en) 2022-12-08
MX2022014734A (es) 2023-03-15

Similar Documents

Publication Publication Date Title
JP7624033B2 (ja) Pd-1阻害剤を投与することによって皮膚がんを処置する方法
JP7384949B2 (ja) 肺癌の処置のための抗pd-1抗体
US20220249659A1 (en) Combination of pd-1 inhibitors and lag-3 inhibitors for enhanced efficacy in treating cancer
JP2023011902A (ja) Pd-1阻害剤を投与することにより子宮頸がんを処置する方法
IL323023A (en) Combination of PD-1 and LAG-3 inhibitors for improved efficacy in melanoma treatment
US20250326846A1 (en) Methods of treating cancer in immunosuppressed or immunocompromised patients by administering a pd-1 inhibitor
RU2833461C1 (ru) Способы лечения рака шейки матки путем введения инибитора pd-1
CN117043193A (zh) 通过施用新辅助pd-1抑制剂治疗癌症的方法
US20250270321A1 (en) Methods of treating lung cancer by administering a pd-1 inhibitor
RU2771759C2 (ru) Антитела против pd-1 для лечения рака легких
TW202517679A (zh) 以抗ilt2抗體治療癌症
EA049388B1 (ru) Способы лечения базально-клеточной карциномы путем введения антитела или его антигенсвязывающего фрагмента, специфически связывающихся с pd-1

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211025

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20211025

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20211025

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220725

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220809

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20221109

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221109

C876 Explanation why request for accelerated appeal examination is justified

Free format text: JAPANESE INTERMEDIATE CODE: C876

Effective date: 20221109

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221117

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221122

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20221209

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20221213

C305 Report on accelerated appeal examination

Free format text: JAPANESE INTERMEDIATE CODE: C305

Effective date: 20221213

C22 Notice of designation (change) of administrative judge

Free format text: JAPANESE INTERMEDIATE CODE: C22

Effective date: 20221220

C13 Notice of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: C13

Effective date: 20230104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230113

C23 Notice of termination of proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C23

Effective date: 20230124

C03 Trial/appeal decision taken

Free format text: JAPANESE INTERMEDIATE CODE: C03

Effective date: 20230221

C30A Notification sent

Free format text: JAPANESE INTERMEDIATE CODE: C3012

Effective date: 20230221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230303

R150 Certificate of patent or registration of utility model

Ref document number: 7240512

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150